Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
- DOI
- 10.1086/318527
- Published
- 2001 Feb 15
- Container
- The Journal of infectious diseases
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1086/318527,
title = {Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.},
author = {Henry K and Wallace RJ and Bellman PC and Norris D and Fisher RL and Ross LL and Liao Q and Shaefer MS and TARGET Study Team},
year = {2001},
journal = {The Journal of infectious diseases},
doi = {10.1086/318527},
url = {https://doi.org/10.1086/318527}
}RIS
TY - JOUR TI - Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. AU - Henry K AU - Wallace RJ AU - Bellman PC AU - Norris D AU - Fisher RL AU - Ross LL AU - Liao Q AU - Shaefer MS AU - TARGET Study Team PY - 2001 JO - The Journal of infectious diseases DO - 10.1086/318527 UR - https://doi.org/10.1086/318527 ER -
APA
K, H., RJ, W., PC, B., D, N., RL, F., LL, R., Q, L., MS, S., & Team, T. S. (2001). Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.. The Journal of infectious diseases. https://doi.org/10.1086/318527
Source records
- pubmed · retrieved 2026-11-10T06:06:38.856Z
- europe-pmc · retrieved 2026-11-10T06:06:38.871Z